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Stephen E. Harding4,5, John R. Helliwell6, Naomi E. Chayen2* & Gary G. Adams1*
This study concerns glulisine, a rapid‑acting insulin analogue that plays a fundamental role in 
diabetes management. We have applied a combination of methods namely X‑ray crystallography, 
and biophysical characterisation to provide a detailed insight into the structure and function of 
glulisine. X‑ray data provided structural information to a resolution of 1.26 Å. Crystals belonged to 
the H3 space group with hexagonal (centred trigonal) cell dimensions a = b = 82.44 and c = 33.65 Å with 
two molecules in the asymmetric unit. A unique position of D21Glu, not present in other fast‑acting 
analogues, pointing inwards rather than to the outside surface was observed. This reduces interactions 
with neighbouring molecules thereby increasing preference of the dimer form. Sedimentation 
velocity/equilibrium studies revealed a trinary system of dimers and hexamers/dihexamers in dynamic 
equilibrium. This new information may lead to better understanding of the pharmacokinetic and 
pharmacodynamic behaviour of glulisine which might aid in improving formulation regarding its fast‑
acting role and reducing side effects of this drug.
Insulin glulisine (IGlu) is a rapid-acting insulin analogue, which differs from human insulin, where the aspara-
gine at position B3 is replaced by lysine and lysine in position B29 is replaced by glutamic acid. Chemically, 
it is 3B-lysine-29B-glutamic acid-human insulin, which, when injected subcutaneously, the onset of action is 
more rapid, and achieves higher concentrations compared to human insulin on a unit-per-unit basis. IGlu is 
an analogue of human insulin, which affects self-association (into dimers) and the isoelectric point, shifting to 
a low pI 5.1 compared to human insulin, pI 5.5, which augments its solubility at a physiological pH. IGlu, like 
human insulin, is formed of two chains, stabilised with two inter-chain, and one intra-chain, disulfide bridges, 
commonly referred to as A and  B1.
IGlu, the recombinant human insulin analogue, has been reported to reduce the propensity to form hexam-
ers (a stable, but ineffective form) and remain as monomers (the effective form), thereby making it a fast-acting 
 analogue2. IGlu takes effect 12–30 min after injection and peaks at 1.6–2.8 h, as opposed to human recombinant 
insulin which takes 30 min to take effect and peaks at between 2.5–5 h3.
Although several characterisation studies have been published on  IGlu4–9, its crystal structure has not been 
reported in detail. We have obtained  crystals10 and in this elucidation study, we identify for the first time, the 
results of crystallography combined with data from analytical ultracentrifugation to provide structural informa-
tion that was previously lacking. The combination of methods provides a detailed and comprehensive insight into 
the structure and function of the IGlu, which can assist in designing an improved formulation as a rapid-acting 
insulin and reducing side effects of this drug.
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Results and discussion
X‑ray crystallography. The presence and integrity of the IGlu sample was confirmed by Mass Spectrom-
etry (Fig. S1, results and methods are shown in Supplementary Information). The atomic structure of IGlu was 
then determined by crystallisation and X-ray diffraction (PDB code 6GV0).
Crystals. Crystals grew after 24  h with typical dimensions of 0.2 × 0.2 × 0.2  mm (Figure  S2). Following 
detailed investigations of the crystallisation phase  diagram10, the best diffracting crystals up to 1.26 Å resulted 
from mixing 1 µL of the protein solution with 1 µL of the crystallisation reservoir solution containing: 0.2 M Mg-
Formate, 0.1 M Bis–Tris buffer pH 5.5 and 8.0% glycerol.
The X-ray diffraction data demonstrates that the IGlu crystal belongs to the H3 space group with hexagonal 
(centred trigonal) cell dimensions a = b = 82.44 Å and c = 33.65 Å, and angles 90, 90, 120 degrees with two mol-
ecules in the asymmetric unit cell (we refer below to Mol1 consisting of chain A and chain B and Mol2 consisting 
of chains C and D).
Positive and negative electron density around the side chains of residue B3 (in Mol1 and Mol2) confirmed 
that indeed this residue was mutated from Asn to Lys. As expected, D3 has electron density which is stronger 
than B3. As for the second mutation, Lys to Glu at position B29 the B29 mutation in Mol2 (which we label as 
D29) mutation was observed while in Mol1 it is not since the C-terminus of the B chain B29 and B30 (from B29 
Cβ) is disordered.
Model building. Strong electron density (> 6σ in Fo–Fc maps) was visible at the known  Zn2+ site and was 
therefore modelled as such. The final model of the IGlu complex consists of 76 water molecules, two  Zn2+ ions—
one for each monomer (shared with two other symmetry related molecules) and two formate ions. Ten amino 
acid residues were modelled in alternate conformations for the dimer in which some alternates were introduced 
into relatively low density of 0.7–8σ due to flexibility of the residues. The C-terminus of chains B and D (long 
chains of insulin monomers) also shows some flexibility around residues B29 and the last residue Thr30 of both 
chains (B30 and D30) could not be modelled into electron density.
Overall parameters for the diffraction statistics and the final model are listed in Table 1. A representative 
section of the final electron density map is shown in Figure S3a.
The overall structure of the glulisine monomer (dimer). In the asymmetric unit of the IGlu crystal 
there are two independent molecules (a dimer): molecule1 (Mol1) comprising of peptide chains A and B and 
Table 1.  Data collection and processing parameters of glulisine.
Beamline Diamond-I04-1
Δφ (°) 0.2
φ0 (°), total frames 180, 900
Rmerge (last shell) % 5.8 (69.1)
〈I/σ(I)〉 (last shell) 13.4 (1.2)
Completeness (last shell) % 99.8 (99.3)
Space group H3
Unit cell
a = b (Å)a = b (Å) 82.44
c (Å) 33.65









Number of Zn ions 2
Number of formate ions 2
Number of water molecules 76
Angle r.m.s.d 1.887
Bond length r.m.s.d 0.023
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molecule2 (Mol2) comprising peptide chains C and D. Chains A and C are identical in sequence, as are chains 
B and D. The A-chain has 21 amino acids and the B-chain has 30 amino acids linked together by two disulfide 
bonds derived from cysteine residues (A7–B7 and A20–B19). In addition, there is one intrachain disulfide bond 
within the A-chain (A6–A11). The A-chain consists of two main α-helices A2Ile to A8Thr and A13Leu to A19Tyr 
connected by a non-canonical turn of A9Ser–A10Ile to stabilise the A6Cys–A11Cys disulfide bond. The B-chain 
of IGlu comprises a main α-helix (B8Gly to B19Cys) and an extended  310 α-helix from B20Gly to B22Arg which 
allows the chain to fold back on itself bringing the B-chain C-terminal close to the N-terminus of A-chain11 
(Fig. 1). The N-terminus of the B-chain of insulin may adopt two alternative conformations designated as the 
T- and R-states. The IGlu B-chain N-terminus is found in the T-state in the crystal. The T-state is where the 
B1Phe-B8Gly residues are in an extended chain while in the R-state the chain has undergone a conversion to 
an allosteric conformation thus extending the B-chain α-helix. T-like state is needed for folding efficiency and 
receptor  binding12.
The electron density and glulisine mutation. High quality electron density of the IGlu dimer was 
obtained and the model was well defined (Figure S3a). The following residues were found with good electron 
density in both of their split conformations: A12Ser, B9Ser, C12Ser, C18Asn and D27Thr while in residues 
B17Leu, D22Arg and B21Glu predominantly one alternate conformation could be modelled well. Thr30 of both 
B and D chains was not visible in the structure (see also PDB codes 4INS, 3ZS2, 1BE9). The C-terminal stretch 
of the B-chain insulin is known for its flexibility. This flexibility is important in insulin activation and self-
association13.
IGlu differs from human insulin by replacing the amino acid asparagine at position B3 with lysine and the 
lysine at position B29 with glutamic acid. These two mutations are better fitted to the model at the D-chain of the 
dimer and all atoms are clearly seen at 0.9–1σ (Figures S3b,c). The B-chain is slightly more disordered thus only 
very weak density is observed for Lys3 NZ. For B29Glu no electron density is obtained from CB to CD. B3Lys 
NZ has only one weak hydrogen bond to the OE1 atom of A15Gln (3.39 Å) while D3Lys has 2 stronger hydrogen 
bonds, one to symmetry water 107 (2.83 Å) and the other to the O1 formate (FMT) ion (2.52 Å) (Fig. 2a). Both 
3Lys are positioned at the surface of the molecule however, although chain B is closer to chain A compared with 
the N-terminal of the D-chain and C-chain, a FMT ion located in the gap between these chains enables better 
contact and thus more stability of the D3Lys side chain. D29Glu makes 2 H-bonds with the C-chain and one 
salt bridge: OE1 to N of A1Gly (2.85 Å), N to OE2 of A4Glu (2.90 Å) and carbonyl O to OE2 of A4Glu (3.31 Å) 
which enables clear observation of the 29Glu mutant (in the density) (Figure S3c, Fig. 2). B29Glu on the other 
hand has only H-bonds to water molecules (218 and 217), which can explain its weak electron density.
Comparison to human insulin. IGlu structure alignment (superposition) with native human insulin 
(PDB codes 4EY9 and 4INS) shows a good overlap in general (for the root mean square deviations of specific 
chains calculated by PDBe fold see Table S1). The main differences observed are located at the C-termini of 
chains B and D. This is in agreement with the B29 mutation influencing the ability of the insulin IGlu for self-
association as the B26Tyr-B30Ala region is important and may thus be more labile for dimerisation and hexamer 
Figure 1.  IGlu dimer with the two-fold like axis (green arrow), A-chain is coloured light grey, B-chain in light 
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formation. Smaller changes but notable ones, can be seen for the extended T region of these chains (residues 
1–8) of the B chain but not (less for) the D.
Comparison to human insulin dimers and hexamers. It was found that residues B8Gly–B9Ser, 
B12Val–B13Glu, B16Tyr, B24Phe–B26Tyr and the C-terminal of the B chain are important for dimer creation 
and residues B1Phe–B7Cys B10His, B14Ala, B17Leu, B20Gly and A13Leu are essential for the hexamers. Super-
position of IGlu, 4EY9 and 4INS show smaller changes for the D8–D12 residues compared with the B-chain 
(Fig. 3a). Nevertheless, IGlu D main chain is slightly diverted at D13Glu (about 0.6 Å distance) between the C 
atoms (same for N atoms) of IGlu and those of 4EY9 and 4INS. In addition, the D13Glu side chain is pointed to 
towards D10His, results in hydrogen bond to the N atom of D13His which is not found for D13Glu of the native 
insulin in 4INS and 4EY9. B13Glu is located at the centre of the hexamer, its side chain position is not conserved 
within the three mentioned structures. B13Glu in 4INS creates an H-bond with its approximate twofold crys-
tallographic symmetry D13Glu (B13Glu OE2 distance to D13Glu OE2 is 2.59 Å) (Fig. 3b). Thus, the hexamer 
cavity is more closed. In insulin 4EY9, the side chain of B13Glu is located further away from the centre and 
thus makes hexamer cavity wider. Interestingly, the α-turn in the IGlu D chain residues D19Cys (from C atom), 
Figure 2.  Hydrogen net bonds of the IGlu two mutations 3Lys and 29Glu for D-chain (a) and B-chain (b). 
Symmetry water 107 is labelled blue. Figure created using Chimera v1.8.1 http://www.cgl.ucsf.edu/chime ra/.
Figure 3.  (a) The overall superposition of IGlu (tan) and human insulin 4INS (light blue) and 4EY9 (purple). 
Main differences are observed at the C-terminal of B/D chains and at D-chain residues 21–22. (b) A zoom along 
the two fold symmetry and the unique hydrogen bonds of D21Glu to B26Tyr and D16Tyr OH. Figure created 
using Chimera v1.8.1 http://www.cgl.ucsf.edu/chime ra/.
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D20Gly, D21Glu and D22Arg is shifted away from the native insulin (4INS, 4EY9) bringing this region close to 
the B-chain pointing towards the inner core. This allows the creation of unique H-bonds between B26Tyr and 
D16Tyr OH groups to D21 OE2, while the human insulin D21Glu side chain points out to the surface of the 
dimer (towards the solvent) [PDB codes 4INS, 4EY9 (Figs. 3a and 4a), 4NIB, 4EWZ,1G7A]. This unique position 
of D21Glu was not observed for the two fast release insulin analogues Lispro and Aspart (PDB codes 5UPD and 
4GBN accordingly, results are not shown). This position of D21Glu prevents the glutamic acid from creating a 
hydrogen bond to another molecule (by symmetry) therefore preferring the dimeric form. Although the D22Arg 
shows an alternate conformation in which one of them (the B) is located where the native D21Glu is, and may 
create contact to a symmetric molecule, the interaction would be very weak compared to the native Glu residue 
(Fig. 4). In addition, the electrostatic surface at this position is altered, as the negative charge of the Glu residue 
is hidden now. The last four labile residues at the C-terminal are probably influenced by the D29Glu (B29) muta-
tion and its salt bridge to A1Gly N that contribute to stabilise the  monomer6. However, this kind of bridge is 
observed for the insulin 4INS with its D30Ala O atom bonded to C1Gly N-terminus. 
The electrostatic surface of IGlu is different than the native insulin because of the two mutations changing the 
neutral, polar, hydrophilic Aspargine at B3 to the basic, polar and hydrophilic lysine while at B29 the basic lysine 
is replaced with the acidic, polar and hydrophilic glutamic acid (Fig. 5a). The additional charge at B3 results in a 
slightly lower isoelectric point (pI) for IGlu of 5.1 compared with native human insulin 5.5. The B3Lys mutation 
also induced subtle steric and electrostatic repulsion between the two monomer  molecules6. Figure 5b shows 
Figure 4.  The unique conformation of IGlu D21Glu (a) and the native insulin D21Glu PDB:4EY9 (b) note their 
differing interactions through water molecules to a neighbouring protein molecule by symmetry. IGlu in yellow, 
insulin (4EY9) in pink and the symmetry related one in blue. Figures created using COOT v0.8.9.1.
Figure 5.  (a) The electrostatic surfaces of the hexamer of IGlu, 4INS and 4EY9 side view (left) and top view 
from the three fold axis (right). (b) D3Lys and B22Arg (symmetry) are both positively charged and in only 
5.07 Å distance which contributes to the electrostatic repulsion. Figures created using COOT v0.8.9.1.
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D3Lys in about 5 Å distance to a symmetry B22Arg that contribute to the electrostatic repulsion as both are 
positively charged (protein–protein electrostatic interactions carrying a charge can occur between molecules that 
are positioned up to 10 Å distance away from each other). Electrostatic surface calculations of IGlu, undertaken 
using  COOT14 also indicate that B10His is basic while the electrostatic surfaces of 4INS and 4EY9 at the core of 
the hexamer are more acidic.
The zincs, ligands, dimers and hexamers. The IGlu formulation is documented as a zinc-free insulin 
analogue for its rapid absorption action. Insulin crystallography has shown that zinc is pivotal for hexamer 
formation. With the B3 and B29 mutations disrupting the formation of dimers (B29) and hexamers (B3), IGlu 
is one of the best fast acting insulin  derivatives5,6. However, our IGlu crystal structure consists of a dimer in the 
asymmetric unit (space group H3) that assembles to a hexamer. The differences between our IGlu and insulin 
are small rather than large differences, such as a different oligomerisation. The standard hexamer consists of six 
insulin molecules arranged as three dimeric units related by a threefold symmetry axis. The dimers possess a 
pseudo-twofold axis (some side chains have different arrangement thus breaking the twofold symmetry e.g. B/
D25Phe side chain), which is perpendicular to the threefold axis of rotation (Figs. 1, 3b, Figure S4). The twofold 
symmetry axis is positioned between the antiparallel β-strands of B-chains. Strong positive electron density next 
to the B10His residue on the threefold axis was observed suggesting that a Zn ion should be modelled not least 
because this structural arrangement in insulin itself binds zinc. Indeed, the anomalous difference Fourier elec-
tron density map shows a strong peak at each of the two binding sites, which matches the classical Zn and with 
occupancy slightly less than the classical 1/3. We note that the X-ray wavelength of 0.92 Å is on the high energy 
side of the zinc K edge at 1.283 Å (i.e. f″ is 2.1 electrons at that X-ray wavelength). This finding must mean that 
traces of zinc ions are present in the commercial, as supplied, formulation solution as no zinc was used in the 
crystallisation.
We note that the commercial supplier does not document its sample with an X-ray fluorescence Scan. Interest-
ingly, this Zn concentration presumably at a trace level, was sufficient for binding and for then ensuring hexamers 
in the crystal. However we also note that Gast et al.5 mentioned that IGlu forms compact hexamers even in the 
absence of  Zn2+ and that in dilution the hexamers rapidly dissociate into monomers. In addition, they found 
that the IGlu association mechanism is different to the other rapid acting insulins. Insulin Aspart (NovoRapid) 
and Lispro (Humalog) (PDB codes 1ZEG and 1LPH, respectively) are both rapid-acting insulins and exist in 
hexameric form in their formulation and in the crystal structures in the presence of zinc but monomerisation 
(hexamer dissociation) is much more rapid in vivo compared to native insulin.
Two formate ions (FMT) from our IGlu crystallisation condition were observed in the electron density. The 
first FMT1 is located at a small pocket-like (D3Lys, C14Tyr, C12Ser, D1Phe) at the IGlu surface creating an 
H-bond with the basic D3Lys mutant. FMT3 is modelled in the middle of the hexamer along the threefold axis 
and creates an H-bond to the B10His ND1 atom (3.53 Å) from symmetry, which may have caused the His10 to be 
more positive as shown in the electrostatic surface. In both cases the FMT ions are located next to a basic residue.
The structure has now been thoroughly examined using X-ray crystallography. However, knowledge of the 
structure still does not provide information on how this analogue behaves in solution, and therefore its function 
in vivo. Hydrodynamic techniques were employed to elucidate this function.
Analytical ultracentrifugation. Sedimentation velocity. Figure 6a shows the c(s) distributions of a con-
centration series, ranging from 0.5–3.5 mg/mL, for IGlu. The distributions follow a consistent pattern of 3 peaks; 
a smaller, well-resolved peak at 1–1.5S and a pair of peaks between 2 and 4.5S. In lower concentrations (0.5, 
1.0 mg/mL) these peaks are of equal height but as concentration increases, the height of the 3.5S peak increases 
a







































Figure 6.  (a) Sedimentation coefficient profiles of IGlu at 7 concentrations between 0.5–3.5 mg/mL. (b) 
Integrated peaks plotted against concentration. Error bars are shown for both apparent sedimentation 
coefficient and concentration, however standard error was < 0.01% of values and therefore the error bars are 
indistinguishable from data points.
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:1737  | https://doi.org/10.1038/s41598-021-81251-2
www.nature.com/scientificreports/
more than the 2.5S peak. This is an indication of association between the two components. To confirm this, all 
three peaks were individually integrated for information on weight-average sedimentation coefficient and con-
centration (area-under-curve, fringe units). These results are plotted in Fig. 6b. Peak 1 shows an extrapolation to 
1.5S at zero concentration from a negative slope, a classic example of non-ideal  behaviour15. Peaks two and three, 
however, show positive slopes and extrapolate to 2.5S and 3.2S, respectively. The positive slope is confirmation 
of self-interaction, as the presence of more insulin in the system increased the proportion of higher molar mass 
stoichiometries.
The presence of an equilibrium of quaternary structures is evidence of the efficacy of IGlu as a fast-acting 
analogue. The complete dissociation into monomers functionalises the protein into the effective form, whereas 
the hexamer/di-hexamer conformations provide a more stable state when present in the sub-cutaneous depot.
HYDROPRO. HYDROPRO was used to estimate the sedimentation coefficients based on the previously 
obtained crystal structure. It estimated that the sedimentation coefficient of the dimer should have been 1.47S 
(based on molar mass of 11,646  Da and partial specific volume of 0.729  mL/g). This is in excellent agree-
ment with peak 1 of the distribution. It can also be inferred that peaks two and three are the hexamer and 
dihexamer, respectively, as following a 2/3rds power scaling law, one would expect peaks of 2.7S for 35 kDa 
and 3.1S for 70 kDa. HYDROPRO also predicted an intrinsic viscosity of 3.822 mL/g, diffusion coefficient of 
11.36 × 10−7 cm2/s, hydrated radius of 1.887 nm and radius of gyration of 1.476 nm. These properties were not 
measured as part of this investigation, however the diffusion coefficient is in agreement with previously obtained 
 results4. The distribution, in terms of quaternary structure, is in disagreement with Nagel et al.16 who ascertained 
a system of monomers, hexamers and dihexamers, obtained through small angle X-ray scattering under similar 
conditions. It is possible there may be some error in sedimentation velocity measurement, related to the high 
proportion of larger oligomeric species, however the strong agreement with HYDROPRO does suggest that 
these results are valid. Alternatively, from the 1.5S peak showing strong concentration dependence and present-
ing as low as 1S at the highest concentration, could suggest some sort of complex monomer–dimer interaction 
which has not been elucidated by either study.
Sedimentation equilibrium. AUC-SE allowed for the determination of molar mass in the systems. The c(M) 
algorithm in SEDFIT-MSTAR was used to determine the baseline, as well as an estimated distribution of species. 
For lower concentrations and lower speeds, the software was unable to resolve individual components, but was 
able to provide point-average, apparent molar masses along the length of the cell (Fig. 7a). The 7 concentra-
tions overlap in a range between 0 and 20 fringes. As would be expected, higher loading concentration samples 
showed higher concentration ranges. Apparent molar masses also ranged between 20 and 50 kDa. Consider-
ing the monomer molar mass of IGlu is 5.8 kDa, the hexameric mass is therefore 34.8 kDa. This suggests the 
distribution of components spans beyond hexamer to potentially di-hexamer assemblies. Such stoichiometries 
are not uncommon with  insulin4,17. This is confirmed in the c(M) distribution analysis (Fig. 7b) where a peak 
is resolved at ~ 30 kDa (an underestimate of a hexamer due to the presence of non-ideality) and another peak 
at ~ 60 kDa (di-hexamer). The smaller peak resolved in AUC-SV is not present, however this may be due to 
the low concentration of the species. In the 22k revolutions per minute (RPM) sub-plot, one can clearly see the 





























































Figure 7.  Output from SEDFIT-MSTAR c(M) analysis of IGlu measured with AUC-SE. (a) Point-average, 
apparent molar mass measured across the cell with overlapping plots from the concentration range 0.5–3.5 mg/
mL). Monomer, dimer, hexamer and dihexamer have been labelled M, D, H and DiH, respectively. (b) c(M) 




Scientific Reports |         (2021) 11:1737  | https://doi.org/10.1038/s41598-021-81251-2
www.nature.com/scientificreports/
In summary, results from analytical ultracentrifugation confirm the presence of dimers, hexamers and di-
hexamers, with the latter two in dynamic equilibrium.
Conclusions
Glulisine (APIDRA) is a rapid-acting human insulin analogue indicated to improve glycaemic control in adults 
and paediatric patients, who present with diabetes mellitus, a condition which results from metabolic aberrations. 
The structural changes of IGlu, namely the replacement of the amino acid asparagine at position B3 by lysine and 
the replacement of lysine in position B29 by glutamic acid, are what effects the rapid-acting nature of this insulin. 
However, there are concerns as to the adverse effects of IGlu and therefore, more detailed analysis was required.
X-ray crystal structure analysis has revealed structural changes compared with insulin and other insulin 
analogues that can explain its rapid-acting role. This includes: firstly, the AsnB3Lys mutation, shows electrostatic 
repulsion to a neighbouring B22Arg. Secondly, the shorter residue Glu in the LysB29Glu mutation leads to fewer 
interactions to a symmetry related molecule (only one weak hydrogen bond to one of the D22Arg conformations 
compared to two to three hydrogen bonds in native insulin PDB 4EY9 and 4INS respectively, Fig. 4). Thirdly, the 
unique conformation of D21Glu now points to the core of the protein rather than outside towards the solvent, 
increasing dimer interactions, “pulling” the C-terminus closer so that D29Glu could make a hydrogen bond to 
the C1Gly N atom. These results are in agreement with AUC-SV analysis showing IGlu in solution as dimers. 
For the higher forms (hexamers and dihexamers) it could be a result of the low concentrations of Zn in solution 
and some interactions of IGlu with neighbouring molecules. These results show that the monomer to monomer 
interactions are weaker compared to native insulin. This can explain its fast dissociation to dimers and monomers 
and thereby its function as a rapid-acting insulin.
For the first time, this research provides novel, structural information on glulisine. This information sheds 
light on the dissociation of glulisine in solution which may be important for optimising drug formulation and 
reducing side effects of this drug. Knowledge of the structure could also be important when considering the 
docking/binding of glulisine with its receptor.
Materials and methods
Glulisine. 10 mL vials of Insulin glulisine (IGlu) were produced by Sanofi Aventis and obtained from a phar-
macy in Nottingham, United Kingdom. Vials were refrigerated at 5 °C until used.
X‑ray crystallography. Crystallisation. All crystallisation experiments were performed by the hanging-
drop vapour-diffusion method by mixing the IGlu solution and the crystallisation agents at 1:1 ratio. Initial 
conditions were found using the commercial Index-I screen (Hampton Research) and construction of phase 
 diagrams10. The crystallisation conditions were further refined by optimizing pH, precipitant concentrations 
and cryo parameters.
Data collection. Crystals were frozen straight from the original drop into liquid nitrogen. X-ray data was col-
lected at 100K on the I04-1 beamline at Diamond Light Source synchrotron (λ = 0.91587 Å). The Pilatus 6M-F 
(active area of 424 × 435 mm2) detector operates in shutterless mode, allowing the collection of a complete data-
set in a few minutes. A total of 900 frames were collected with oscillation range of 0.2° to 180°. Data processing 
was done automatically by the Diamond Xia2 software using mosflm for processing and aimless for  scaling18.
A total of 104,577 accepted reflections (F > 0σ(F)) were measured in the 41.22–1.26 Å resolution range, and 
resulted in 22,987 independent reflections, with 99.8% completeness to resolution range and 99.3% complete-
ness for the highest resolution shell of 3.42–1.26 Å. The overall redundancy in the data set was 4.5, the overall 
mosaicity was 0.066, the average 〈I/σ(I)〉 was 13.4, and the final Rmerge (I +/−) for the whole data was 5.8% 
(69.1% for the highest resolution shell).
Structure determination of glulisine. The structure was solved by molecular replacement using  Phaser19 and 
human insulin crystal structure (PDB entry: 4EY9) as search model, resulting in a clear solution Top LLG: 
1149.97 and Top TFZ: 28.9 (RVAL: 45.1) parameter values and a dimer in the asymmetric unit. This conclusion 
was supported by the Matthews coefficient  calculations20, which revealed that there are two molecules in the 
asymmetric unit, with a reasonable Vm value of 1.89 Å3/Da and estimated solvent content of about 35%. The 
structure was further refined using the Phenix software  package21.
Model building and refinement of glulisine. Real space refinement of the IGlu dimer molecules was conducted 
by visual inspection of both the map and model with  COOT14, which was also used for the addition of formate 
and zinc ions.
Each refinement cycle was followed by manual fitting and rebuilding of the two molecules of the IGlu dimer 
(chains A, B for Mol1 and C, D for Mol2) using COOT.
Further isotropic refinement was carried out with the program PHENIX. Water molecules were added at the 
end of refinement using the automated method provided in PHENIX while formate and Zn ions were added using 
COOT program. The model was further improved by anisotropic temperature factor refinement in PHENIX 
yielding Rwork and Rfree values of 12.79 and 15.18% (for 5% of the data), respectively.
Quality of final models. The stereochemical quality of the model was examined with the program  PROCHECK22, 
allowing a general validation of its main structural parameters and as such is of high quality; see Table 1.
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Calculations and figure preparations. The matrices for the superposition of the insulin and IGlu structures were 
calculated by a least-squares distance minimization algorithm (LSQ, implemented within the program PDBe 
fold), using the C α-atoms as the guide coordinates. Figures were prepared by the "Chimera"  software23,  COOT14 
for electron density and electrostatic surfaces.
Analytical ultracentrifugation. Sedimentation velocity. IGlu was assayed using a Beckman Optima 
XL-I analytical ultracentrifuge (Beckman Coulter, Brea, CA, USA). Data were acquired with ProteomeLab 6.0 
from Rayleigh interference optical scans.
For concentrations ranges, IGlu preparations were concentrated using Centrisart tubes as to separate the 
protein from the excipient-only supernatant. IGlu vials were available at a concentration of 3.5 mg/mL, and 
subsequently diluted, using supernatant, into 6 concentrations (0.5, 1.0, 1.5, 2.0, 2.5, 3.0).
Sedimentation velocity (SV) experiments were performed at 45 k rpm (~ 150 kg) in duplicate. 400 μL of 
sample and reference were injected into AUC cells constructed from two-channel, aluminium-epoxy resin cen-
trepieces, sapphire windows, and aluminium housings. Cells were balanced and aligned in the rotor (An50Ti) 
to match the direction of centrifugal force. Scans were performed every two minutes for 10 h.
SV data were analysed using SEDFIT v15.4. Continuous distribution of sedimentation coefficients analysis, 
c(s) vs s, was performed to identify  peaks24. Peaks were integrated to calculate the absolute and relative concen-
tration c, %, respectively. Values were corrected to standard conditions (water, 20 °C) to correct for density ρ 
and viscosity η variations (Eq. 1). A concentration series was also performed to calculate ks according to Eq. (2).
where s is the sedimentation coefficient, in temperature and buffer conditions T,b, extrapolated to infinite dilu-
tion 0.
HYDROPRO. Hydropro25 was used to estimate the sedimentation coefficient based on the crystal structure 
(from the PDB file) from a bead model of atomic positions. Partial specific volume was 0.729 mL/g and molar 
mass was 11,646 Da.
Sedimentation equilibrium. Sedimentation equilibrium (SE) experiments were performed on the same cen-
trifuge as sedimentation velocity, except at 15k, 18k and 22 krpm. The same cells and rotor, as described above, 
were used but with 120 μL of sample and reference used. Scans were performed every hour until equilibrium was 
achieved i.e. no net movement of macromolecular material (~ 24 h).
Data were analysed using SEDFIT-MSTAR 26. SEDFIT-MSTAR was capable of yielding weight-average, z-aver-
age molar masses, and low-resolution c(M) distributions (c = area-under-curve) from SE curves.
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